3Blom JW,Doggen CJ,Osanto S,et al.Malignancies,prothrombotic mutations,and the risk of venous thrombosis.JAMA,2005,293:715-722.
4Levitan N,Dowlati A,Remick SC,et al.Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy.Risk analysis using Medicare claims data.Medicine (Baltimore),1999,78:285-291.
5Wells PS,Hirsh J,Anderson DR,et al.Accuracy of clinical assessment of deep-vein thrombosis.Lancet,1995,345:1326-1330.
6Lee AY,Levine MN.Management of venous thromboembolism in cancer patients.Oncology(Williston Park),2000,14:409-417,421,422,425-426.
7Koopman MM,Prandoni P,Piovella F,et al.Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home.The Tasman Study Group.N Engl J Med,1996,334:682-687.
8Merli G,Spiro TE,Olsson CG,et al.Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.Ann Intern Med,2001,134:191-202.
9Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.The Columbus Investigators.N Engl J Med,1997,337:657-662.
10Hutten BA,Prins MH,Gent M,et al.Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio:a retrospective analysis.J Clin Oncol,2000,18:3078-3083.
